Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK

por Wilson, Michele R, Azzabi Zouraq, Ismail, Chevrou-Severac, Helene, Selby, Ross, Kerrigan, Matthew C
Publicado 2017

Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model

por Wilson, Michele R, Patel, Jeetvan G, Coleman, Amber, McDade, Cheryl L, Stanford, Richard H, Earnshaw, Stephanie R
Publicado 2017

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium

por Wilson, Michele R., McDade, Cheryl L., Perdrizet, Johnna E., Mignon, Annick, Farkouh, Raymond A., Wasserman, Matt D.
Publicado 2021

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease

por Huang, Liping, McDade, Cheryl L., Perdrizet, Johnna E., Wilson, Michele R., Warren, Sophie A., Nzenze, Susan, Sewdas, Renilla
Publicado 2023

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium

por Wasserman, Matt D., Sings, Heather L., Wilson, Michele R., Postma, Maarten J., Breton, Marie-Claude, McDade, Cheryl, Farkouh, Raymond A.
Publicado 2018

Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis

por Wilson, Michele R., Wasserman, Matthew D., Breton, Marie-Claude, Peloquin, Francois, Earnshaw, Stephanie R., McDade, Cheryl, Sings, Heather L., Farkouh, Raymond A.
Publicado 2020

Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”

por Wilson, Michele R., Wasserman, Matt, Jadavji, Taj, Postma, Maarten, Breton, Marie-Claude, Peloquin, Francois, Earnshaw, Stephanie R., McDade, Cheryl, Sings, Heather L., Farkouh, Raymond
Publicado 2018